While the interim analysis of data following the completion of treatment of the first 21 patients demonstrated disease stabilization, the study did not achieve the primary tumor response endpoint. NeoPharm said no new patient accrual will be made into this study.
Patients currently receiving therapy will continue treatment per protocol until a study endpoint is reached. NeoPharm said it will be reassessing project next steps including additional data analyses and the possibility of other studies.